



NC State Medical Oncology is enrolling patients for a clinical trial of an experimental immunotherapy for the treatment of bladder cancer. The primary purpose of this study is to investigate the safety and immune-stimulating properties of a novel therapy being developed at NCSU. There will be multiple dosing groups during this study.

The immunotherapy uses an immune stimulant (called IL-12) mixed in a bio adhesive solution that allows it to stick to the bladder walls, including the cancer, and 'turn-on' anti-cancer immune cells just under the surface. *All dogs will receive immunotherapy.*

PARTICIPATION:

- 12-day study, minimum of 3 days hospitalization.
 - Return for outpatient samples on day 4 and 8.
 - May include outpatient sample collection on day 5 and 12.
- 3 dogs per dosing group.
 - Can re-enroll AFTER 3 dogs have finished the study.
- General anesthesia or sedation for U-Cath purposes.
- IL-12 infused into bladder and removed after 1 hour.
- Owner diary and questionnaire's to be completed.
- Multiple blood draws and urine collection.

ELIGIBILITY:

- Any breed or sex.
- Weigh more than 8 kgs.
- Histologically diagnosed.
- Can be invasive.
- Can have been previously treated with chemo, radiation, etc.
 - 1 month wash out of RT and/or chemotherapy.
- Can have metastases.
- End stage or new.

For additional information contact the Clinical Studies Core:

cvmclinicalstudies@ncsu.edu or 919-515-3634